Healthpoint today announced that it has initiated a clinical trial assessing the effectiveness of Collagenase SANTYL® Ointment, as compared to vehicle, on the change from baseline in wound area of diabetic foot ulcers (DFU) over four weeks. The trial will also follow subjects to determine the proportion that achieve complete wound closure within 12 weeks of initiating treatment. One of the long-term complications of diabetes is the development of foot ulcers primarily as a consequence of peripheral neuropathy due to prolonged serum glucose elevation.

News
Tue, 08/10/2010
|
||
|
Tue, 03/30/2010
Healthpoint, Ltd., a Fort Worth-based company committed to advancing the science and innovation of wound care, was recently named to Training Magazine’s Top 125 List for 2010. This is the first year that Healthpoint applied to be named to the Training Top 125, finishing 104 among all companies. The 2010 Training Top 125 is an annual ranking that honors organizations that offer outstanding employer-sponsored workforce training and development. Other companies recognized in the Top 125 include Microsoft, Cisco, Bank of America, and the US Navy. |
||
|
Mon, 02/22/2010
Healthpoint, Ltd. was recently named as one of the Best Companies to Work for in Texas 2010. This awards program was created in 2006 as a collaboration between Texas Monthly Magazine, the Texas Association of Business, the Texas State Council of the Society for Human Resource Management and Best Companies Group. |
||
Tue, 02/16/2010
Healthpoint today announced it has provided research grants to the University of Florida, Gainesville, and Vanderbilt University School of Medicine to support a joint study evaluating bioburden and potential healing markers in chronic wounds. This research initiative will explore the hypothesis that bacterial biofilms are associated with the breakdown of key components on cells and in the extracellular matrix (ECM) that regulate wound healing.
|
||
|
Wed, 01/27/2010
Healthpoint today announced that it will begin marketing Collagenase SANTYL® Ointment to healthcare professionals in Canada. SANTYL® Ointment is a selective enzymatic agent indicated for debriding chronic dermal ulcers (e.g., pressure ulcers, vascular ulcers, and diabetic ulcers) and severely burned areas, and is now the only enzymatic debrider available in the Canadian market. |
